Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budoprutug - Climb Bio

Next Previous
Drug Profile

Budoprutug - Climb Bio

Alternative Names: TNT-119

Latest Information Update: 18 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tenet Medicines
  • Developer Climb Bio
  • Class Anti-inflammatories; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Membranous glomerulonephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Membranous glomerulonephritis
  • Phase I/II Idiopathic thrombocytopenic purpura
  • Phase I Systemic lupus erythematosus
  • Phase 0 Autoimmune disorders

Most Recent Events

  • 07 Nov 2025 Climb Bio plans a phase-III trial for Membranous glomerulonephritis (IV),
  • 25 Aug 2025 Phase-II clinical trials in Membranous glomerulonephritis in USA (IV), (NCT07096843)
  • 12 Aug 2025 Climb Bio plans a phase I trial in (In volunteers) in first half of 2026 (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top